| Mr Charles Kevin Owens, PT | |
|
115 Huston Dr, Suite 3, Shepherdsville, KY 40165-7250 | |
| (502) 921-0272 | |
| (502) 921-0465 |
| Full Name | Mr Charles Kevin Owens |
|---|---|
| Gender | Male |
| Speciality | Physical Therapy |
| Experience | 17 Years |
| Location | 115 Huston Dr, Shepherdsville, Kentucky |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1629010889 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 225100000X | Physical Therapist | 004421 (Kentucky) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Sn Kentuckiana Rehab Llc | 1254671464 | 248 |
News Archive
Today, The U.S. Food and Drug Administration approved a novel therapy for patients with metastatic pancreatic adenocarcinoma – the most common form of pancreatic cancer – whose disease has progressed following gemcitabine-based therapy, offering new hope against a disease that will claim the lives of more than 40,000 individuals this year.
Fourteen to 18-year-old adolescents are at an increased risk to initiate smoking when they start to work, according to researchers from the Johns Hopkins Bloomberg School of Public Health.
Inspired by nature, an international research team has created synthetic pores that mimic the activity of cellular ion channels, which play a vital role in human health by severely restricting the types of materials allowed to enter cells.
Depomed, Inc. today announced that it has closed the acquisition of the U.S. rights to the NUCYNTA franchise from Janssen Pharmaceuticals, Inc. for $1.05 billion. The NUCYNTA franchise includes: NUCYNTA ER (tapentadol) extended release tablets indicated for the management of pain, including neuropathic pain associated with diabetic peripheral neuropathy (DPN), severe enough to require daily, around-the-clock, long-term opioid treatment; NUCYNTA (tapentadol), an immediate release version of tapentadol, for management of moderate to severe acute pain in adults; and NUCYNTA (tapentadol) oral solution, an approved oral form of tapentadol that has not been launched.
A study published online in The FASEB Journal delves into the mystifying fact that wounds in your mouth heal faster and more efficiently than wounds elsewhere.
› Verified 5 days ago
| Provider Name | Sn Kentuckiana Rehab Llc |
|---|---|
| Provider Type | Part B Supplier - Physical/occupational Therapy Group In Private Practice |
| Provider Identifiers | NPI Number: 1609349018 PECOS PAC ID: 1254671464 Enrollment ID: O20190326002841 |
News Archive
Today, The U.S. Food and Drug Administration approved a novel therapy for patients with metastatic pancreatic adenocarcinoma – the most common form of pancreatic cancer – whose disease has progressed following gemcitabine-based therapy, offering new hope against a disease that will claim the lives of more than 40,000 individuals this year.
Fourteen to 18-year-old adolescents are at an increased risk to initiate smoking when they start to work, according to researchers from the Johns Hopkins Bloomberg School of Public Health.
Inspired by nature, an international research team has created synthetic pores that mimic the activity of cellular ion channels, which play a vital role in human health by severely restricting the types of materials allowed to enter cells.
Depomed, Inc. today announced that it has closed the acquisition of the U.S. rights to the NUCYNTA franchise from Janssen Pharmaceuticals, Inc. for $1.05 billion. The NUCYNTA franchise includes: NUCYNTA ER (tapentadol) extended release tablets indicated for the management of pain, including neuropathic pain associated with diabetic peripheral neuropathy (DPN), severe enough to require daily, around-the-clock, long-term opioid treatment; NUCYNTA (tapentadol), an immediate release version of tapentadol, for management of moderate to severe acute pain in adults; and NUCYNTA (tapentadol) oral solution, an approved oral form of tapentadol that has not been launched.
A study published online in The FASEB Journal delves into the mystifying fact that wounds in your mouth heal faster and more efficiently than wounds elsewhere.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mr Charles Kevin Owens, PT 10504 Firview Ct, Louisville, KY 40299-5843 Ph: (502) 741-6897 | Mr Charles Kevin Owens, PT 115 Huston Dr, Suite 3, Shepherdsville, KY 40165-7250 Ph: (502) 921-0272 |
News Archive
Today, The U.S. Food and Drug Administration approved a novel therapy for patients with metastatic pancreatic adenocarcinoma – the most common form of pancreatic cancer – whose disease has progressed following gemcitabine-based therapy, offering new hope against a disease that will claim the lives of more than 40,000 individuals this year.
Fourteen to 18-year-old adolescents are at an increased risk to initiate smoking when they start to work, according to researchers from the Johns Hopkins Bloomberg School of Public Health.
Inspired by nature, an international research team has created synthetic pores that mimic the activity of cellular ion channels, which play a vital role in human health by severely restricting the types of materials allowed to enter cells.
Depomed, Inc. today announced that it has closed the acquisition of the U.S. rights to the NUCYNTA franchise from Janssen Pharmaceuticals, Inc. for $1.05 billion. The NUCYNTA franchise includes: NUCYNTA ER (tapentadol) extended release tablets indicated for the management of pain, including neuropathic pain associated with diabetic peripheral neuropathy (DPN), severe enough to require daily, around-the-clock, long-term opioid treatment; NUCYNTA (tapentadol), an immediate release version of tapentadol, for management of moderate to severe acute pain in adults; and NUCYNTA (tapentadol) oral solution, an approved oral form of tapentadol that has not been launched.
A study published online in The FASEB Journal delves into the mystifying fact that wounds in your mouth heal faster and more efficiently than wounds elsewhere.
› Verified 5 days ago
Dr. Nathan Glen Hobbs, PT, DPT Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 115 Huston Dr, Shepherdsville, KY 40165 Phone: 502-921-0272 | |
Mrs. Amy Lynn Morris, PTA Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 1905 West Hebron Lane, Suite 106, Shepherdsville, KY 40165 Phone: 502-955-7705 Fax: 502-957-1257 | |
Jacob Travis Huellemeier, PT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 431 Adam Shepherd Pkwy Ste 1, Shepherdsville, KY 40165 Phone: 502-921-0272 | |
Mrs. Dana Jobe Arnold, PT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 1905 West Hebron Lane, Suite 106, Shepherdsville, KY 40165 Phone: 502-955-7705 Fax: 502-957-1257 | |
Jennifer Kara, DPT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 1707 Cedar Grove Rd, Shepherdsville, KY 40165 Phone: 502-633-1007 | |
Mrs. Raven Leigh Powell, PT, DPT Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 1868 W Hebron Ln Unit 101, Shepherdsville, KY 40165 Phone: 318-201-9919 | |
Logan D Wright, DPT Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 115 Huston Dr Ste 3, Shepherdsville, KY 40165 Phone: 502-921-0272 |